Actively Recruiting
Early Detection of Complications During Immunotherapy for Haematological Malignancy
Led by Rigshospitalet, Denmark · Updated on 2026-03-13
100
Participants Needed
1
Research Sites
134 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Aims * To identify patients that should remain admitted in hospital for more intense surveillance because of high risk for development of clinical complications * Expand the understanding of the interactions between physiology and immunology for the design of future projects and general knowledge Hypothesis Development of a risk model based on a combination of physiological and immunological parameters can contribute to early detection of patients at risk for clinical complications after anti-cancer treatment.
CONDITIONS
Official Title
Early Detection of Complications During Immunotherapy for Haematological Malignancy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 60; 18 years
- Diagnosed with haematologic malignant disease (e.g. malignant lymphoma)
- Scheduled for treatment with CART or BsAbs
You will not qualify if you...
- Pregnant
- Has a pacemaker
- Allergic to any materials in the monitoring equipment
- Unable to comply with study participation as deemed by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rigshospitalet
Copenhagen O, Denmark, 2100
Actively Recruiting
Research Team
S
Sandra Egedie Lyby Taylor Pitter, MD
CONTACT
E
Eske K Aasvang, Professor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here